Wang Gangzheng, Sun Chengyuan, Xie Bojun, Wang Tao, Liu Hongwei, Chen Xianglian, Huang Qiuju, Zhang Chenghua, Li Taihui, Deng Wangqiu
Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, State Key Laboratory of Applied Microbiology Southern China, Institute of Microbiology, Guangdong Academy of Sciences, Guangzhou, China.
State Key Laboratory of Mycology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Front Nutr. 2022 Nov 2;9:1038740. doi: 10.3389/fnut.2022.1038740. eCollection 2022.
Obesity has caused serious health and economic problems in the world. is a high-value macrofungus with broad application potential in the food and bio-medicine industry. This current study aimed to estimate the role of lipid-lowering compound formula (CGLC) in regulating fat and lipid accumulation, gut microbiota balance, short-chain fatty acid (SCFA) contents, and expression levels of genes involved in fat and lipid metabolism in high-fat diet (HFD) mice. The results showed that CGLC intervention markedly reduced body weights and fat accumulation in HFD mice, improved glucose tolerance and blood lipid levels, and decreased lipid droplet accumulation and fat vacuole levels in the liver. CGLC decreased the ratio of Firmicutes and Bacteroidetes and increased the relative abundances of () and (). In addition, CGLC treatment significantly promoted the production of SCFAs and regulated the relative expression levels of genes involved in fat and lipid metabolism in liver. Association analysis showed that several species of and most of SCFAs were significantly associated with serum lipid indicators. These results suggested that CGLC is a novel candidate formulation for treating obesity and non-alcohol fatty liver by regulating gut microbiota, SCFAs, and genes involved in fat and lipid metabolism.
Am J Transl Res. 2025-5-15
Metabolites. 2024-7-27
J Fungi (Basel). 2024-5-16
Front Endocrinol (Lausanne). 2023
Front Pharmacol. 2022-6-6